BAP1 and PBRM1 in metastatic clear cell renal cell carcinoma: tumor heterogeneity and concordance with paired primary tumor

被引：0
|
作者：
Jeanette E. Eckel-Passow
Daniel J. Serie
John C. Cheville
Thai H. Ho
Payal Kapur
James Brugarolas
R. Houston Thompson
Bradley C. Leibovich
Eugene D. Kwon
Richard W. Joseph
Alexander S. Parker
机构：
[1] Mayo Clinic,Division of Biomedical Statistics and Informatics
[2] Mayo Clinic,Department of Health Sciences Research
[3] Mayo Clinic,Laboratory Medicine and Pathology
[4] Mayo Clinic,Division of Hematology and Medical Oncology
[5] University of Texas Southwestern Medical Center,Department of Pathology
[6] University of Texas Southwestern Medical Center,Kidney Cancer Program, Simmons Comprehensive Cancer Center
[7] University of Texas Southwestern Medical Center,Division of Hematology
[8] Mayo Clinic,Oncology
[9] Mayo Clinic,Department of Urology
来源：
BMC Urology | / 17卷
关键词：
Clonal; Prognostic; Immunohistochemistry;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] Expression of Bap1 in Clear Cell Renal Cell Carcinoma
    Fatima, Arooj
    JOURNAL OF PATHOLOGY, 2024, 264 : S12 - S12
  • [22] High concordance of BAP1 and PBRM1 expression in patient-matched primary and metastatic ccRCC tumors.
    Shreders, Amanda
    Joseph, Richard Wayne
    Serie, Daniel
    Kapur, Payal
    Ho, Thai Huu
    Eckel-Passow, Jeanette
    Brugarolas, James
    Parker, Alexander S.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
  • [23] Inactivation of PBRM1, a gene frequently mutated in clear cell renal carcinoma, suppresses tumor growth
    Huang Dachuan
    Kiat, Ong Choon
    Bin Tean, Teh
    Huimin, Bernice Wong
    Chan-on, Waraporn
    Subimerb, Chutima
    Furge, Kyle
    Futreal, Andrew
    CANCER RESEARCH, 2011, 71
  • [24] Prognostic and Predictive Value of PBRM1 in Clear Cell Renal Cell Carcinoma
    Carril-Ajuria, Lucia
    Santos, Maria
    Maria Roldan-Romero, Juan
    Rodriguez-Antona, Cristina
    de Velasco, Guillermo
    CANCERS, 2020, 12 (01)
  • [25] Analysis of gene expression changes as a function of PBRM1, BAP1, and SETD2 mutation status clear cell renal cell carcinoma in TCGA tumors
    Abbosh, Philip H.
    Ibragimova, Ilsiya
    Slifker, Michael
    Cairns, Paul
    CANCER RESEARCH, 2015, 75
  • [26] Expression of the tumor suppressor PBRM1 in relation to clinicopathological features of clear cell renal cell carcinomas
    Hoegner, Anica
    Krause, Hans
    Jandrig, Burkhard
    Fuller, Tom Florian
    Patzak, Andreas
    Kilic, Ergin
    BJU INTERNATIONAL, 2015, 116 : 12 - 12
  • [27] The expanding role of BAP1 in clear cell renal cell carcinoma
    Kapur, Payal
    Rajaram, Satwik
    Brugarolas, James
    HUMAN PATHOLOGY, 2023, 133 : 22 - 31
  • [28] PBRM1, SETD2 and BAP1-the trinity of 3p in clear cell renal cell carcinoma
    Walton, Joseph
    Lawson, Keith
    Prinos, Panagiotis
    Finelli, Antonio
    Arrowsmith, Cheryl
    Ailles, Laurie
    NATURE REVIEWS UROLOGY, 2023, 20 (02) : 96 - 115
  • [29] Mutational Analysis of PBRM1 and Significance of PBRM1 Mutation in Anti-PD-1 Immunotherapy of Clear Cell Renal Cell Carcinoma
    Aili, Abudureyimujiang
    Wen, Jie
    Xue, Lixiang
    Wang, Junjie
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [30] The impact of PBRM1 and BAP1 expression on outcomes of patients with metastatic renal cell carcinoma (mRCC) treated with VEGF-targeted therapy (TT).
    Fay, Andre Poisl
    de Velasco, Guillermo
    Gray, Kathryn P.
    Ho, Thai Huu
    Song, Jiaxi
    Kapur, Payal
    Albiges, Laurence
    McDermott, David F.
    Heng, Daniel Yick Chin
    Brugarolas, James
    Choueiri, Toni K.
    Signoretti, Sabina
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
12345